US 2023/0416341 A1 · IMPROVED THROMBIN INHIBITORS FOR TREATMENT OF THROMBOEMBOLIC CONDITIONS

Abstract

The invention relates to the treatment of thromboembolic conditions, to fibrin clot formation and related thrombin activity, and to preparation of compounds, in particular, peptides and polypeptides for inhibiting, or for modifying the cleavage of fibrinogen by thrombin.

Claims24

Dependent claims

A peptide comprising, consisting essentially of, or consisting of an amino acid sequence shown in SEQ ID No:

1 or SEQ ID No:
2.

Dependencies are inferred from the claim text.

Facts

Application

18/011,073Filed 19 Jun 2020

Published

28 Dec 2023

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 14/811
Endopeptidase inhibitors: serine protease inhibitors
A61K 38/55
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: protease inhibitors
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 7/02
Drugs for disorders of the blood or the extracellular fluid: antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

Claims24

Dependent claims

A peptide comprising, consisting essentially of, or consisting of an amino acid sequence shown in SEQ ID No:

1 or SEQ ID No:
2.

Dependencies are inferred from the claim text.

Improved thrombin inhibitors for treatment of thromboembolic conditions

Life of this patent

Abstract

Claims24

Improved thrombin inhibitors for treatment of thromboembolic conditions

Life of this patent

Abstract

Claims24